FDG PET or PET/CT in patients with pancreatic cancer: when does it add to diagnostic CT or MRI?

详细信息    查看全文

• 作者：Omar Javery^a ; ^{ojavery@partners.org} ; Paul Shyn^b ; ^{pshyn@partners.org} ; Koenraad Mortele^c ; ^{kmortele@bidmc.harvard.edu}
• 关键词：PET/CT ; Pancreatic cancer ; Clinical management
• 刊名：Clinical Imaging
• 出版年：2013
• 出版时间：March-April, 2013
• 年：2013
• 卷：37
• 期：2
• 页码：295-301
• 全文大小：624 K

文摘

Objective

Assess the impact of FDG-PET or PET/CT (PI) on pancreatic cancer management when added to CT or MRI (CDI).

Materials and Methods

Forty-nine patients underwent 79 PI exams. Discordant findings on PI and CDI were assessed for clinical impact.

Results

Fifteen of 79 PI-CDI pairs were discordant. Ten of 79 PI favorably and 5 of 79 unfavorably altered management. PI favorably altered management more often when ordered for therapy monitoring compared to staging [risk ratio 13.00 (95 % CI 1.77-95.30)] or restaging [risk ratio 18.5 (95 % CI 2.50-137.22)].

Conclusion

PI favorably alters management more often when used for therapy monitoring compared to staging or restaging.